Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 2.18 3.32% 0.07
APTO closed up 3.32 percent on Tuesday, March 19, 2019, on 1.27 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical APTO trend table...

Date Alert Name Type % Chg
Mar 19 MACD Bullish Centerline Cross Bullish 0.00%
Mar 19 Pocket Pivot Bullish Swing Setup 0.00%
Mar 19 Spinning Top Other 0.00%
Mar 19 Upper Bollinger Band Walk Strength 0.00%
Mar 19 Weak + Overbought Other 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Above Upper BB Strength 0.00%
Mar 19 Gapped Up Strength 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%

Older signals for APTO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Medicine Biopharmaceutical Cancer Clinical Medicine Drugs Solid Tumors Immunotherapy Oncology Acute Myeloid Leukemia Pancreatic Cancer Targeted Therapy Bemcentinib Phosphoinositide 3 Kinase Inhibitor Treatment Of Acute Myeloid Leukemia Treatment Of Pancreatic Cancer Anticancer Therapies Pancreatic Cancers Preclinical Stage Products Small Molecule Therapies
Is APTO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.55
52 Week Low 1.57
Average Volume 278,062
200-Day Moving Average 2.57
50-Day Moving Average 1.974
20-Day Moving Average 1.8305
10-Day Moving Average 1.829
Average True Range 0.1227
ADX 23.96
+DI 33.0288
-DI 11.9777
Chandelier Exit (Long, 3 ATRs ) 1.8819
Chandelier Exit (Short, 3 ATRs ) 1.9381
Upper Bollinger Band 2.1336
Lower Bollinger Band 1.5274
Percent B (%b) 1.08
BandWidth 33.116635
MACD Line 0.0147
MACD Signal Line -0.0443
MACD Histogram 0.0589
Fundamentals Value
Market Cap 52.38 Million
Num Shares 24 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -2.79
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.35
Resistance 3 (R3) 2.35 2.30 2.32
Resistance 2 (R2) 2.30 2.26 2.30 2.31
Resistance 1 (R1) 2.24 2.23 2.22 2.24 2.30
Pivot Point 2.19 2.19 2.18 2.19 2.19
Support 1 (S1) 2.13 2.15 2.11 2.13 2.06
Support 2 (S2) 2.08 2.12 2.08 2.05
Support 3 (S3) 2.02 2.08 2.04
Support 4 (S4) 2.02